Drug intelligence / Profile preview

sonidegib + fluorouracil + leucovorin + oxaliplatin + irinotecan

Development stage: Phase 1
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Combination therapy consisting of sonidegib (LDE225), a potent selective and orally bioavailable SMO antagonist that inhibits the Hedgehog signaling pathway, with FOLFIRINOX chemotherapy (fluorouracil, leucovorin, oxaliplatin, and irinotecan). This combination targets both the tumor stroma (via sonidegib) and cancer cells directly (via FOLFIRINOX) in pancreatic cancer. Sonidegib specifically inhibits the Smoothened (SMO) protein, blocking Hedgehog pathway signaling which is involved in the desmoplastic reaction in pancreatic cancer.

Other names: sonidegib + FOLFIRINOX

Targets

DNASMO (Smoothened)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on sonidegib + fluorouracil + leucovorin + oxaliplatin + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sonidegib + fluorouracil + leucovorin + oxaliplatin + irinotecan.